I'm Too Young for This!: The Natural Hormone Solution to Enjoy Perimenopause (31 page)

Dach, Jeffrey, MD. “Hormone Replacement Therapy HRT Does NOT Cause Breast Cancer, New Study,”
Jeffrey Dach MD Bioidentical Hormone Blog
, posted March 16, 2012.

Faloon, William. “The Unscientific Bioidentical Hormone Debate,”
Life Extension Magazine
, October 2009.

Life Extension Foundation. “Bioidentical Hormones: Why Are They Still Controversial,”
Life Extension Magazine
, October 2009.

Moskowitz, Deborah, MD. “A Comprehensive Review of the Safety and Efficacy of Bioidentical Hormones,”
American College for Advancement in Medicine IM Blog
, August 12, 2011.

Ruiz, Andres D., Kelly R. Daniels, Jamie C. Barner et al. “Effectiveness of Compounded Bioidentical Hormone Replacement Therapy: An Observational Cohort Study,”
BMC Women’s Health
11 (2011): 27.

Bakken, K., A. Fournier, E. Lund et al. “Menopausal Hormone Therapy and Breast Cancer Risk: Impact of Different Treatments: The European Prospective Investigation into Cancer and Nutrition,”
International Journal of Cancer
128, no. 1 (January 2011): 144–156.

Batur, P., C. E. Blixen, H. C. Moore et al. “Menopausal Hormone Therapy (HT) in Patients with Breast Cancer,”
Maturitas
53, no. 2 (January 20, 2006) 123–132.

Beral, V., and Million Women Study Collaborators. “Breast Cancer and Hormone-Replacement Therapy in the Million Women Study,”
Lancet
362, no. 9382 (August 9, 2003): 419–427.

Brooke, D. G., E. J. Shelley, C. G. Roberts et al. “Synthesis and In Vitro Evaluation of Analogues of Avocado-Produced Toxin (+)-(R)-persin in Human Breast Cancer Cells,”
Bioorganic and Medicinal Chemistry
19, no. 23 (December 1, 2011): 7033–7043.

Chlebowski, Rowan T., MD, PhD; Susan L. Hendrix, DO; Robert D. Langer, MD, MPH et al. “Cancer and Mammography in Healthy Postmenopausal Women,”
Journal of the American Medical Association
289, no. 24 (June 25, 2003): 3243–3253.

Christante, D., S. Pommier, J. Garreau et al. “Improved Breast Cancer Survival Among Hormone Replacement Therapy Users Is Durable After 5 Years of Additional Follow-Up,”
American Journal of Surgery
196, no. 4 (October 2008): 505–511.

Clemente, C., F. Russo, M. G. Caruso et al. “Ceruloplasmin Serum Level in Post-Menopausal Women Treated with Oral Estrogens Administered
at Different Times,”
Hormone and Metabolic Research
24, no. 4 (April 1992): 191–193.

De Leo, M., R. Pibonello, R. S. Auriemma et al. “Cardiovascular Disease in Cushing’s Syndrome: Heart Versus Vasculature,”
Neuroendocrinology
92, supp. 1 (2010): 50–54.

Dew, J. E., B. G. Wren, and J. A. Eden. “Tamoxifen, Hormone Receptors and Hormone Replacement Therapy in Women Previously Treated for Breast Cancer: A Cohort Study,”
Climacteric
5, no. 2 (June 2002): 151–155.

Durna, E. M., G. Z. Heller, L. R. Leader et al. “Breast Cancer in Pre-menopausal Women: Recurrence and Survival Rates and Relationship to Hormone Replacement Therapy,”
Climacteric
7, no. 3 (September 2004): 284–291.

Espié, M., J. P. Daures, T. Chevallier et al. “Breast Cancer Incidence and Hormone Replacement Therapy: Results from the MISSION Study, Prospective Phase,”
Gynecological Endocrinology
23, no. 7 (July 2007): 391–397.

Fournier, A., F. Berrino, and F. Clavel-Chapelon. “Unequal Risks for Breast Cancer Associated with Different Hormone Replacement Therapies: Results from the E3N Cohort Study,”
Breast Cancer Research and Treatment
107, no. 1 (January 2008): 103–111.

Hadhazy, Adam. “Think Twice: How the Gut’s ‘Second Brain’ Influences Mood and Well-Being,”
scientificamerican.com
(February 12, 2010).
www.scientificamerican.com/article.cfm?id=gut-second-brain
.

Ives, Jeffrey C., PhD; Mark Alderman, MS, ATC; and Susan E. Stred, MD. “Hypopituitarism After Multiple Concussions: A Retrospective Case Study in an Adolescent Male,”
Journal of Athletic Training
42, no. 3 (July–Sept. 2007): 431–439.

Jick, H., A. M. Walker, and K. J. Rothman. “The Epidemic of Endometrial Cancer: A Commentary,”
American Journal of Public Health
70, no. 3 (March 1980): 264–267.

Mason, G. A., C. H. Walker, and A. J. Prange Jr. “L-triiodothyronine: Is This Peripheral Hormone a Central Neurotransmitter?”
Neuropsychopharmacology
8, no. 3 (May 1993): 253–258.

McCarthy, M. M. “Estrogen Modulation of Oxytocin and Its Relation to Behavior,”
Advances in Experimental Medicine and Biology
395 (1995): 235–245.

Menna, M. Abdel-Dayem, and Mohamed S. Elgendy. “Effects of Chronic Estradiol Treatment on the Thyroid Gland Structure and Function of Ovariectomized Rats,”
BMC Research Notes
, published online (August 30, 2009).
www.biomedicalcentral.com/1756-0500/2/173
.

Meyers, David G., Daniel Strickland, Pierre A. Maloley et al. “Possible Association of a Reduction in Cardiovascular Events with Blood Donation,”
Heart
78 (1997): 188–193.

Persson, Ingemar, Jonathan Yuen, Leif Bergkvist et al. “Cancer Incidence and Mortality in Women Receiving Estrogen and Estrogen-Progestin Replacement Therapy—Long-Term Follow-up of a Swedish Cohort,”
International Journal of Cancer
67, no. 3 (July 29, 1996): 327–332.

Rossouw, J. E., G. L. Anderson, R. L. Prentice et al. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial,”
Journal of the American Medical Association
288, no. 3 (July 17, 2002): 321–323. For more information about the Women’s Health Initiative, visit
www.nhlbi.nih.gov
.

Saeki, Toshiaki, Muneo Sano, Yoshifumi Komoike et al. “No Increase of Breast Cancer Incidence in Japanese Women Who Received Hormone Replacement Therapy: Overview of a Case-Control Study of Breast Cancer Risk in Japan,”
International Journal of Clinical Oncology
13, no. 1 (February 2008): 8–11.

Salonen, Jukka T., Tomi-Pekka Tuomainen, Riitta Salonen et al. “Donation of Blood Is Associated with Reduced Risk of Myocardial Infarction,”
American Journal of Epidemiology
148, no. 5 (1998): 445–451.

Schairer, C., H. O. Adami, R. Hoover, and I. Persson. “Cause-Specific Mortality in Women Receiving Hormone Replacement Therapy,”
Epidemiology
8, no. 1 (January 1997): 59–65.

Schairer, C., J. Lubin, R. Troisi et al. “Menopausal Estrogen and Estrogen-Progestin Replacement Therapy and Breast Cancer Risk,”
Journal of the American Medical Association
283, no. 4, (January 26, 2000): 485–491.

Sintzel, F., M. Mallaret, T. Bougerol. “Potentializing of Tricyclics and Serotoninergics by Thyroid Hormones in Resistant Depressive Disorders,”
Encephale
30, no. 3 (May–June 2004): 267–275.

University of Maryland Medical Center. “Dehydroepiandrosterone,”
www.umm.edu
(April 7, 2011).
www.umm.edu/altmed/articles/dehydroepiandrosterone-000299.htm
.

Vighi, G., F. Marcucci, L. Sensi, G. Di Cara, and F. Frati. “Allergy and the Gastrointestinal System,”
Clinical and Experimental Immunology
153, supp. 1 (September 2008): 3–6.

Vongpatanasin W., M. Tuncel, Z. Wang et al. “Differential Effects of Oral Versus Transdermal Estrogen Replacement Therapy on C-Reactive Protein in Postmenopausal Women,”
Journal of the American College of Cardiology
41, no. 8 (April 2003): 1358–1363.

Wassertheil-Smoller, Sylvia, PhD; Susan Hendrix, DO; Marian Limacher, MD et al. “Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women,”
Journal of the American Medical Association
289, no. 20 (May 28, 2003): 2673–2684.

Willis, D. B., E. E. Calle, H. L. Miracle-McMahill, and C. W. Heath Jr. “Estrogen Replacement Therapy and Risk of Fatal Breast Cancer in a Prospective Cohort of Postmenopausal Women in the United States,”
Cancer Causes and Control
7, no. 4 (July 1996): 449–457.